RBC Capital upgraded Bio-Techne, citing M&A confidence, margin gains, and growth potential after a sharp stock drop and alignment with sector valuations.
Latest Ratings for TECH
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 2022 | SVB Leerink | Maintains | Outperform | |
| Sep 2021 | Keybanc | Upgrades | Sector Weight | Overweight |
| Jun 2021 | SVB Leerink | Maintains | Outperform |
